Hematologic Malignancies

ASCO 2024

Questions discussed in this category

Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?

2 Answers available

Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

1 Answer available

Papers discussed in this category

Lancet (London, England), 2019 Dec 10

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Blood, 2023 Jan 19

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

The New England journal of medicine, 2024 Jun 01

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2024 Jun 02

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Related Topics in Hematologic Malignancies